Mirati Gets MHRA Approval for Krazati to Treat Non-Small Cell Lung Cancer Patients

By Stephen Nakrosis


Mirati Therapeutics said on Friday the U.K.’s Medicines and Healthcare Products Regulatory Agency gave conditional marketing approval for Krazati to treat certain non-small cell lung cancer patients.

Krazati was given approval as a treatment for adult patients who have “advanced non-small cell lung cancer with KRAS(G12C) mutation and have progressive disease after prior therapy with, or intolerance to, platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy,” the company said.

In December, Krazati received approval from the Food and Drug Administration as a treatment for certain adult patients with non-small cell lung cancer.

The biotechnology company said lung cancer is one of the most common cancers worldwide.


Write to Stephen Nakrosis at [email protected]


Read the full article here